Saponin-Based Vaccine Adjuvants Patents: Top Companies & Trends 2026
- A 35-year-old anchor patent still dominates citations. US5057540A, filed by Antigenics, carries 3,010 citations — more than ten times the next most-cited record in this set.
- Filing activity is thin and recent. The field only reached its peak year, 2023, with 7 records, after several earlier years with none at all.
- One IPC subclass anchors nearly the whole field. All 37 records in scope sit in A61K, but structural chemistry classes like C07J (steroids) reach only 32.4% — a gap between formulation claims and synthesis claims.
A narrow, citation-heavy field built on one foundational patent
Saponin-based adjuvants, particularly QS-21 derived from the bark of Quillaja saponaria, sit in a technically demanding corner of vaccine formulation: hemolytic activity, cholesterol interaction and supply-constrained raw material all have to be solved together before a formulation is viable. The patent record reflects that difficulty. Across 2015 to 2026, only 37 published records meet the search criteria, and the ranking of assignees names 18 companies with activity concentrated toward a handful of filers.
Because publication typically lags filing by around 18 months, the most recent filing years in this dataset understate real activity. The 2023 peak of 7 records is the strongest signal available, but 2024 through 2026 should be read as still filling in.
Filing trend and technology composition
Two views of the same 37-record set: how filing activity has moved year over year, and how those records distribute across IPC subclasses.
Filing trend, 2017-2026
Filings were flat at zero in 2017 and stayed sparse through most of the window, reaching a peak of 7 records in 2023. The gaps between active years point to a field driven by occasional foundational filings rather than steady incremental activity.
Technology composition by IPC subclass
Every record in scope carries an A61K classification (medicinal preparations), and 83.8% also carry A61P (therapeutic activity). Sugar and undetermined-structure compound classes (C07H, C07G) each cover 51.4% of records, while steroid chemistry (C07J) reaches 32.4% and enzymatic synthesis (C12P) 21.6% — since records can carry multiple classes, these shares add up to more than 100% of the 37 records.
Shares are the percentage of the 37 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Saponin-Based Vaccine Adjuvants with Eureka
This page is one run against one query. Ask Eureka your own question about saponin-based vaccine adjuvants and every answer comes back with the patent numbers behind it.
Try EurekaThe record that still shapes the field
US5057540A — Saponin adjuvant
Substantially pure saponins are disclosed. The saponins of the present invention are useful as immune adjuvants. Disclosed as well are immune response-provoking compositions comprising an antigen in admixture with the substantially pure saponins.Filed by Antigenics, Inc. and granted 1991-10-15, this record has drawn 3,010 citations — an order of magnitude above every other record in this set, including its own related family members EP0362279B1 (390) and EP0362279A1 (126).
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5057540A | Saponin adjuvant | 3,010 |
| 2 | EP0362279B1 | Saponin adjuvant | 390 |
| 3 | US6231859B1 | Saponin adjuvant compositions | 172 |
| 4 | WO1988009336A1 | Saponin adjuvant | 161 |
| 5 | EP0362279A1 | Saponin adjuvant | 126 |
| 6 | US5352449A | Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant | 55 |
| 7 | US5817314A | Quillaja saponin adjuvant and vaccine formulation containing same | 26 |
| 8 | US4432969A | Pharmaceutical compositions | 24 |
| 9 | EP0362279B2 | Saponin adjuvant | 19 |
| 10 | EP0058021A2 | Pharmaceutical compositions | 11 |
Citation counts favour older records that have had more time to accumulate references — treat them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once the ranking, the trend and the IPC composition are read together.
One filer holds a visible lead
The top-ranked assignee in this 18-company ranking holds 10 records, while fifth place has only 3 and tenth place has 2. That gap suggests the leader's position rests on breadth of filing rather than a single blocking patent, since the citation leader (Antigenics' US5057540A) and the volume leader are not necessarily the same entity.
Synthesis routes are less crowded than formulations
Every record touches A61K medicinal-preparation claims, but steroid chemistry (C07J) and fermentation/enzymatic synthesis (C12P, 21.6%) cover far fewer records. For a team working on synthetic or semi-synthetic saponin routes rather than extraction-based formulations, this is measurable open space rather than a guess.
The field has not sustained a filing rhythm
With fewer than four complete years of data once publication lag is factored in, no reliable growth trend can be stated. What is visible is a peak at 7 records in 2023 following years with none — a pattern more consistent with episodic foundational filings than a maturing, continuously-filed technology.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to saponin-based vaccine adjuvants, with the prior art for and against each one.
Who is filing, and where the activity has gone quiet
The assignee ranking spans 18 companies, from a clear leader at 10 records down to single-digit tallies. Momentum data shows several named assignees, including the leader, at zero filings in the latest year — consistent with the overall thinning of recent activity across the dataset.
A clear leader by filing count
The top-ranked assignee holds 10 of the 37 records in scope, well ahead of the rest of the ranked field. That volume does not by itself indicate the strongest individual claims — the most-cited record in the dataset belongs to a different assignee, Antigenics.
A long tail of small-volume filers
Filing drops off quickly after the top few positions: fifth place holds 3 records and tenth place holds 2. This shape points to a field where a handful of specialist or academic-linked entities file occasionally rather than a broad competitive set filing continuously.
Activity has gone quiet across several leaders
Several assignees tracked for year-over-year momentum, including the overall volume leader, show zero filings in the latest year. Combined with the thin recent trend across the whole dataset, this suggests any newly active filer would be entering a field with little current competitive pressure from the historical leaders.
| Assignee | Recent year | YoY |
|---|---|---|
| Access to Advanced Health Institute | 0 | -100% |
| LG Chem Ltd. | 0 | — |
| CAMBRIDGE BIOSCIENCE CORP | 0 | — |
| Beecham Group PLC | 0 | — |
| CAMBRIDGE BIOTECH CORP | 0 | — |
| YOON HYE SUNG | 0 | — |
| YOUNG SUN KWON | 0 | — |
| JOONG MYUNG CHO | 0 | — |
Turning this landscape into a filing decision
The dataset shows where claim density sits and where it thins out. Translating that into a specific filing or freedom-to-operate position takes a closer read of the claims themselves.
Map claims against the under-claimed branches
The gate chips above point to sub-areas with lower IPC coverage than the core formulation classes. Confirming whether that gap is genuine white space, or simply unclassified, requires reading the actual claim language in those adjacent families.
Explore the technology in EurekaTrack the quiet leaders
Several top assignees show zero recent filings. Whether that reflects a lapsed program, a shift to trade secret, or portfolio pruning changes how much weight to put on their older claims today.
Set up assignee tracking in EurekaCommon questions about saponin adjuvant patents
The foundational record in this dataset is US5057540A, 'Saponin adjuvant', filed by Antigenics, Inc. and granted on 1991-10-15. It has accumulated 3,010 citations, far more than any other record in scope, including its related European family members EP0362279B1 and EP0362279A1. That citation gap makes it the single most influential prior-art reference anyone working on saponin adjuvant formulations needs to review first.
It depends on which part of the process. Formulation claims under A61K cover all 37 records in this dataset, so that layer is heavily occupied. Structural and synthesis-route classes such as C07J (steroids, 32.4% of records) and C12P (fermentation and enzymatic synthesis, 21.6%) have noticeably lower coverage, suggesting more room to file on synthetic or semi-synthetic production routes than on formulation itself.
The assignee ranking for this dataset lists 18 companies across 37 total records, so it is a small field by patent-landscape standards. The leader holds 10 records, but filing counts drop quickly, with fifth place at only 3 and tenth place at 2. This is a long-tail structure rather than a field with many equally active competitors.
US5057540A claims substantially pure saponins used as immune adjuvants and compositions combining an antigen with those purified saponins. Anyone formulating a saponin-based adjuvant that relies on a similarly purified saponin fraction mixed with an antigen needs to check this claim scope and its citing family carefully. Because the patent dates to 1991, its core term has expired in most jurisdictions, but its citation network still shapes how later claims in this space were drafted and examined.
Based on IPC coverage, the branches furthest from full coverage are enzymatic or fermentation-based synthesis (C12P, 21.6% of records) and steroid-chemistry routes (C07J, 32.4%), compared to 100% coverage on core A61K formulation claims. Dose-sparing and nanoparticle-assembly angles are also mentioned in the search criteria but are not reflected as dominant IPC classes, suggesting they may be under-classified rather than fully claimed. Anyone considering a synthetic-route or dose-sparing filing should verify this by reading the actual claim sets in the lower-coverage classes, not just the class labels.
Research Saponin-Based Vaccine Adjuvants in depth with Eureka
Go past this page: query the whole saponin-based vaccine adjuvants corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.